Spero Therapeutics, Inc. Balance Sheet
SPRO|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Spero Therapeutics, Inc. had $69M in total assets and $46M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M | $85.2M | $29.7M | $34.1M |
| Current Assets | $67.3M | $107.3M | $131.2M | $113.6M | $157.9M | $139.1M | $95.4M | $124.2M |
| PP&E (Net) | - | - | $2.0K | $368.0K | $1.0M | $1.7M | $2.3M | $2.9M |
| Total Assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M | $153.5M | $106.1M | $129.0M |
| Current Liabilities | $8.9M | $49.1M | $37.2M | $21.6M | $18.7M | $14.3M | $26.7M | $12.3M |
| Shareholders' Equity | $46.1M | $106.9M | $75.9M | $88.3M | $132.0M | $74.6M | $74.6M | $115.5M |